Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.50
Bid: 50.30
Ask: 50.40
Change: 1.45 (2.96%)
Spread: 0.10 (0.199%)
Open: 47.20
High: 50.70
Low: 47.20
Prev. Close: 49.05
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio co First Light completes $45m fund raise

14 Feb 2022 07:00

RNS Number : 5012B
IP Group PLC
14 February 2022
 

FOR RELEASE ON

14 February 2022

 

 

IP Group plc - Portfolio company First Light Fusion

completes $45m (£33m*) fund raise

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that portfolio company First Light Fusion Ltd, a global leader in researching energy generation via inertial fusion, has completed its Series C fund raise, raising $45m (£33m*) from both existing and new investors.

 

As announced on 29 November 2021, IP Group committed £5m to the funding round and, following completion, has an undiluted beneficial holding of 27.4%. IP Group has recorded a net unrealised fair value gain of £27.2m** or 3p per share.

 

The round was also supported by existing investors Oxford Science Enterprises (formerly OSI) and Hostplus as well as new investors Braavos Capital and Tencent.

 

First Light's approach to fusion, which is safe, clean, and a virtually limitless source of energy, has the potential to transform the world's energy system. Unlike existing nuclear, there is no long-lived waste, no meltdown risk, and raw materials can be found in abundance. Unlike many other fusion approaches, First Light's power plant will largely leverage existing technology and materials.

The new funding will be used to accelerate the development of First Light's "gain" experiment, whereby the amount of energy generated outstrips that used to spark the reaction, and to perform further design and engineering work on a 'first of a kind' commercial fusion energy power plant based on its technology.

 

*GBP equivalent using 1.36 USD/GBP

**Fair value gains are quoted net of the Group's long-term incentive carry scheme ('LTICS'). 

 

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKDBKFBKDOBD
Date   Source Headline
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2
26th Mar 202112:26 pmRNSEMA positive opinion for Diurnal's Chronocort
10th Mar 20217:00 amRNSAnnual Results
4th Mar 20216:07 pmRNSHolding(s) in Company
2nd Mar 202112:03 pmRNSHolding(s) in Company
24th Feb 202110:33 amRNSNotice of Results
18th Feb 20214:31 pmRNSHolding(s) in Company
18th Feb 20218:00 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSPortfolio company ApcinteX acquired by Centessa
10th Feb 20217:00 amRNSIP Group, Inc. raises $50.0m (£36.5m*) of funding
9th Feb 20213:52 pmRNSHolding(s) in Company
2nd Feb 20215:15 pmRNSHolding(s) in Company
11th Jan 20215:29 pmRNSHolding(s) in Company
6th Jan 20214:57 pmRNSPortfolio co Hinge Health completes $300m round
6th Jan 202111:34 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSPortfolio co Oxbotica completes £36m funding round
4th Dec 202011:41 amRNSHolding(s) in Company
3rd Dec 20208:01 amRNSArtios and Merck in global strategic collaboration
25th Nov 20207:00 amRNSDirector Declaration
23rd Nov 20205:05 pmRNSHolding(s) in Company
21st Oct 20207:00 amRNSInvestor webinar
13th Oct 20207:00 amRNSOxford Nanopore funding round and contract win
9th Oct 20209:46 amRNSOxford Nanopore's LamPORE test gains CE-IVD mark
7th Oct 20207:00 amRNSEnterprise Therapeutics' program acquired by Roche
23rd Sep 20201:40 pmRNSHolding(s) in Company
15th Sep 202012:07 pmRNSSecond Price Monitoring Extn
15th Sep 202012:02 pmRNSPrice Monitoring Extension
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20205:18 pmRNSForm 8.3 - Modern Water plc
5th Aug 20207:00 amRNSHalf-yearly results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.